Introduction
============

Photodynamic therapy (PDT) is a minimally invasive treatment with fewer side effects ([@b1-ol-0-0-10004]). PDT is known to be effective on many types of cancers including esophageal and gastric cancer ([@b2-ol-0-0-10004]). Early gastric cancer with a nominal risk of metastatic malignancy can be cured by local treatment such as endoscopic resections, including endoscopic submucosal dissection (ESD) ([@b3-ol-0-0-10004]) or PDT ([@b2-ol-0-0-10004]). Compared to endoscopic resections, PDT controls technical quality more easily. However, PDT using the first-generation photosensitizer, porfimer sodium, and excimer dye laser has several problems such as a high occurrence of skin phototoxicity, a long sun shade period and the necessity of an expensive and large laser system for excitation ([@b2-ol-0-0-10004]). In contrast, the second-generation photosensitizer, talaporfin sodium (TS) is rapidly cleared from the skin, requiring shorter sun shade period. Furthermore, the antitumor effect can be deeper through the submucosal layer even to the muscularis propria because the excited wavelength of diode laser is longer (664 nm) than excimer dye laser (630 nm). Recently, Yano *et al* successfully performed a phase II study to evaluate the efficacy and safety of TS-PDT using a diode laser for local failure after chemoradiotherapy (CRT) or radiotherapy (RT) alone, against esophageal cancer ([@b4-ol-0-0-10004]). In 2015, TS-PDT was approved by Ministry of Health, Labour and Welfare (MHLW) in Japan for this indication setting. In addition, it has been already adapted for brain glioblastoma and lung cancer; however, TS-PDT has not been approved for gastric cancer by MHLW despite its medical needs.

Matsumoto *et al* established an experimental system to evaluate antitumor effect of TS-PDT for biliary tract cancer cells *in vitro*, and reported that TS-PDT induced rather high tumor necrosis and apoptosis; it also inhibited cellular proliferation efficiently ([@b5-ol-0-0-10004]). However, TS-PDT effect has not been evaluated in gastric cancer cells *in vitro*.

In this study, we used the above established *in vitro* system to evaluate the antitumor effect of TS-PDT on gastric cancer cells, MKN45 and MKN74. As there were differences of the antitumor effect between these two cell lines, we assessed the underlying mechanisms especially in the viewpoint of low-density lipoprotein (LDL) receptor mediated-uptake of TS. Since porphyrins have high affinity to the LDL receptor ([@b6-ol-0-0-10004]), TS could be bound by the LDL receptor as well.

Furthermore, we used GW3965 and simvastatin to evaluate the effect of LDL receptor expression. GW3965 is agonist/activator of Liver X Receptor (LXR) which inhibits the LDL receptor pathway through transcriptional induction of inducible degrader of the LDL receptor ([@b7-ol-0-0-10004],[@b8-ol-0-0-10004]). Simvastatin is an HMG-CoA (hydroxymethylglutaryl-Coenzyme A) reductase inhibitor, which is a therapeutic agent for hypercholesterolemia by virtue of enhancing the expression of LDL receptor and absorbing blood cholesterol ([@b9-ol-0-0-10004]).

Materials and methods
=====================

### Human gastric cancer cell lines and cultures

MKN45-Luc and MKN74/CMV-Luc cells were obtained from JCRB cell bank. Cells were grown in RPIM-1640 medium supplemented with 10% fetal bovine serum and 1% L-glutamine solution without antibiotics. The cells were cultured in a humidified incubator with 5% CO~2~ at 37°C.

### Reagents

TS, GW3965 (10054) and simvastatin (196--17801) were purchased from Meiji Seika Pharma Co., Ltd. (Tokyo, Japan), Cayman Chemical Co. (Ann Arbor, Michigan, USA), and Fujifilm Wako Pure Chemical Co., Ltd. (Osaka, Japan), respectively. Rabbit monoclonal anti-LDL-receptor antibody (ab52818; Abcam PLC, Tokyo, Japan), rabbit monoclonal anti-β-actin (D6A8) antibody (8457; CST Japan Co., Ltd., Tokyo, Japan) and horseradish peroxidase (HRP)-conjugated goat anti-Rabbit IgG H&L (ab97051; Abcam PLC) were purchased for western blotting analysis.

### Microscopic imaging

Cells were visualized under a fluorescent microscope (BZ-X710; Keyence Co., Osaka, Japan) with the filters included BZ-X filter GFP and for TS (OP-87763 and OP-87767; Keyence Co.). The latter has excitation filter (405BP20) and fluorescence filter (RPE630LP). The software BZ-analyzer (Keyence Co.) was used for merging, reducing noise and enhancing the signal intensity.

### PDT protocol and proliferation assay

Cells were treated with GW3965 and simvastatin reagent for 22 h as this is the earliest time at which the effect can be observed and cultured for 4 h with TS in serum-free medium, 660 nm light (LEDR-660DL; Optocode Co., Ltd., Tokyo, Japan) was irradiated at 2.53 J/cm^2^ ([@b5-ol-0-0-10004]) and cell viability was measured by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay. We usually evaluate the effect of TS-PDT 24 h after LED irradiation, but for simvastatin, the effect was clearly observed 48 h after LED irradiation. MTS Assay was performed as below; 20 µl proliferation assay solution (G3580, CellTiter 96^®^ AQueous One Solution Cell Proliferation Assay; Promega Co., Tokyo, Japan) added to 100 µl culture medium, and after an hour, absorbance of 490 nm was measured by microplate reader (Vientonano; DS Pharma Biochemical Co., Ltd., Osaka, Japan). Finally, we calculated the viability against control cell.

### Fluorescent staining of intracellular organelle

Cells were treated by lysosome staining reagent (C10507, CellLight™ Lysosome-GFP, BacMam 2.0; Thermo Fisher Scientific, Inc.). This reagent is a fusion constructed with lysosomal associated membrane protein 1 and emGFP, providing specific targeting to cellular lysosomes, and is packaged in the insect virus baculovirus. We added this reagent to cells, incubated the cells overnight, and then observed GFP-tagged lysosomes in the cells using a fluorescent microscopy and a standard GFP filter set. We observed that TS had a porphyrin structure showing fluorescence, and emitted red light at 630 nm when excitation light irradiation was at 405 nm.

### Western blotting analysis

Cultured cells were directly lysed for 15 min on ice with RIPA Lysis and Extraction Buffer (89900; Thermo Fisher Scientific Inc., Tokyo, Japan) containing with cOmplete™ ULTRA Tablets, Mini, EASYpack Protease Inhibitor Cocktail and PhoSTOP (05892970001 and 4906845001; Roche Diagnostics Co., Ltd., Tokyo, Japan). After centrifugation at 21,500 × g for 15 min, protein concentrations were measured using Pierce 660 nm Protein Assay Reagent (1861426; Thermo Fisher Scientific, Inc.), and protein was denatured by boiling for 5 min. Equal weights of protein (40 µg) protein was loaded onto sodium dodecyl sulfate-polyacrylamide gels for electrophoresis and then transferred onto nitrocellulose membranes. After blocking with 5% milk in TBST (150 mmol/l NaCl and 50 mmol/l Tris-HCl containing 0.05% Tween-20), the membranes were incubated with anti-LDL receptor antibody (dilution, 1:1,000) and anti-β-Actin antibody (dilution, 1:1,000) at 4°C overnight. After washing with TBST 3 times (5 min each), the membranes were incubated with their corresponding HRP-conjugated secondary antibodies (dilution, 1:5,000) at room temperature for 1 h. After washing with TBST 3 times (5 min each), bound antibodies were visualized using Clarity Western ECL Substrate (1705061; Bio-Rad Laboratories, Inc., Tokyo, Japan) and image analyzer (LAS-3000 mini; Fujifilm Co. Ltd., Tokyo, Japan).

### RNA extraction

Total RNA from cultured cells was extracted using miRNeasy Mini Kit (217004; Qiagen Co., Ltd., Tokyo, Japan). The RNA was quantified using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Inc.). Extracted RNA samples were stored at −80°C until used.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

cDNAs were prepared from total RNA using High-Capacity cDNA Reverse Transcription Kit (4374966; Thermo Fisher Scientific, Inc.). The RT reactions were performed in aliquots containing 2,000 ng of total RNA, 1X RT buffer, 4 mM dNTP mix, 1X RT random primer, 50 units multiscribe reverse transcriptase, 20 units RNase inhibitor, and nuclease-free water added up to 20 µl at 25°C for 10 min, followed by 37°C for 120 min and 85°C for 5 min. Primer sequences for quantitative PCR are below, LDL receptor forward, CCCGACCCCTACCCACTT and reverse, AATAACACAAATGCCAAATGTACACA; and β-actin forward, GCATCCTCACCCTGAAGTA and reverse, TGTGGTGCCAGATTTTCTCC. qPCR reaction was performed in 20 µl aliquots containing 1 µl RT products with 4 µl LightCycler^®^ FastStart DNA MasterPLUS SYBR-Green I (03515869001; Roche Diagnostics Co., Ltd.), 0.5 µM each primer and 14.6 µl nuclease-free water and run on the Real-Time PCR Lightcycler 1.5 Complete System (Roche Diagnostics Co., Ltd.). Thermal cycling was initiated with a first denaturation step at 95°C for 10 min, followed by 45 cycles of 95°C for 10 sec, 60°C, 10 sec and 72°C, 10 sec. The cycle passing threshold (C~t~) was recorded for mRNA by LightCycler Software version 3.5.28 (Roche Diagnostics Co., Ltd.) and β-actin was used as the endogenous control for data normalization. Relative expression was calculated using the formula 2^−ΔΔCt^=2^−(ΔCt,\ reagent\ treatment−ΔCt,\ control)^ ([@b10-ol-0-0-10004]).

### Statistical analysis

The differences between groups were analyzed using the paired, two-tailed, Student\'s t-test. The differences among three groups were analyzed using one-way analysis of variance followed by Tukey\'s post hoc test. Data were expressed as means ± standard error. Differences were considered statistically significant at P\<0.05.

Results
=======

### Differences of PDT efficacy between MKN-45 and MKN-74 cells

As shown in [Fig. 1A](#f1-ol-0-0-10004){ref-type="fig"}, the effect of TS-PDT at 2.53 J/cm^2^ on MKN74 cells was less than on MKN45; cellular viabilities were not decreased within 20 µM of TS concentration. Using higher concentration (30 µM) of TS, MKN74 cells showed enhancement of the effect ([Fig. 1A](#f1-ol-0-0-10004){ref-type="fig"}). In the longest treatment time of 24 h at 10 µM of TS, cellular viability was decreased significantly ([Fig. 1B](#f1-ol-0-0-10004){ref-type="fig"}). In addition, when irradiation power of LED raised up to 5.06 J/cm^2^ at 10 µM of TS, TS-PDT induced the decrease in cellular viabilities even on MKN74 cells ([Fig. 1C](#f1-ol-0-0-10004){ref-type="fig"}). In summary, MKN74 cells seemed rather resistant to TS-PDT compared to MKN45 cells.

### LDL receptor is associated with uptake of TS

As shown with longer treatment time with TS, the difference in the effects between MKN45 and MKN74 cells could be due to the ability of cellular uptake of TS. Considering the correspondence of location and their mergence in color, similar to LDL intracellular movement ([@b11-ol-0-0-10004]), TS was carried into the lysosome ([Fig. 2A](#f2-ol-0-0-10004){ref-type="fig"}). In fact, uptake of TS in MKN74 cells at 4 h was lower than MKN45 cells at this particular time-point ([Fig. 2B](#f2-ol-0-0-10004){ref-type="fig"}). The uptake tended to be increased at the time-point of 24 h. In addition, we confirmed that the expression levels of LDL receptor protein and mRNA in MKN74 cells were lower than MKN45 cells, respectively ([Fig. 2C and D](#f2-ol-0-0-10004){ref-type="fig"}).

### Decreased LDL receptor by GW3965 induces PDT-resistant

Furthermore, we used GW3965 to confirm whether LDL receptor could be related to uptake of TS. As expected, LDL receptor expression was reduced by GW3965 treatment as shown in [Fig. 3A](#f3-ol-0-0-10004){ref-type="fig"}. Subsequently, GW3965 treatment significantly increased cellular viabilities on MKN45 cells (from 10 to 30 µM concentration of TS) and MKN74 cells at 30 µM TS ([Fig. 3B and C](#f3-ol-0-0-10004){ref-type="fig"}).

### Increased LDL receptor by simvastatin enhances efficacy of PDT

When these cells were treated with simvastatin at 20 µM, both protein and mRNA expression levels of LDL receptor were substantially increased ([Fig. 4A and B](#f4-ol-0-0-10004){ref-type="fig"}, respectively). Simvastatin significantly decreased cellular viabilities, and enhanced the PDT effects, on MKN74 cells ([Fig. 4D](#f4-ol-0-0-10004){ref-type="fig"}). On the other hand, simvastatin did not affect cellular viabilities on MKN45 cells as shown in [Fig. 4C](#f4-ol-0-0-10004){ref-type="fig"}.

Discussion
==========

In this paper, we elucidated that LDL receptor expression is involved in the effect with TS-PDT, and simvastatin enhances the therapeutic effect on TS-PDT resistant cell.

PDT has been shown to be a safe and effective treatment for early gastric cancer, not only for the intramucosal type, but also for the submucosal invasion. PDT using the excimer-dye laser and Photofrin^®^ (porfimer sodium, the first-generation photosensitizer) can be an endoscopic treatment option for gastric cancer particularly in a rapidly aging society like Japan ([@b2-ol-0-0-10004]). In clinical practice, PDT is administered at 40 mg/m^2^ of TS per person and 100 J/cm^2^ of laser light. This concentration is similar to that in *in vitro* conditions. However, the LED power is different. This is because we need to eradicate cancer cells in clinical practice completely, but need fewer effective conditions for evaluating reagents *in vitro*. In addition, cells are cultured in a monolayer fashion *in vitro*. Therefore, we think that we need less LED power in *in vitro* system compared to that in clinical practice.

As PDT using TS on gastric cancer is yet to be approved by MHLW in Japan, and currently is not available in clinical settings, therefore we investigated the effects of TS-PDT on gastric cancer cell. In the present study, MKN74 cells were shown to be resistant to TS-PDT. There were substantial differences in expression levels of LDL receptor between MKN74 cells and TS-PDT-sensitive MKN45 cells. TS was localized in the lysosome possibly after being taken by LDL receptor. Downregulation of LDL receptor by GW3965 significantly decreased the effect of TS-PDT in gastric cancer cells. Furthermore, LDL receptor expression was decreased by siRNA knockdown ([Fig. S1](#SD1-ol-0-0-10004){ref-type="supplementary-material"}). The viability was increased from 52.0±6.25 to 56.8±5.11% for MKN45 cells (n=6). We were able to observe an up-trend of viability although not statistically significant while LDL receptor expression was decreased by siRNA. The effect of GW3965 might have been caused by other molecules and receptor contributing to the resistance. On the other hand, simvastatin-mediated LDL receptor upregulation enhanced the effect of PDT in MKN74 cells but not in MKN45 cells, in which LDL receptor could be sufficiently expressed. Therefore, the difference of LDL receptor expression between these two gastric cell lines could affect TS-PDT efficacy.

In our experiments, simvastatin did not have such a dramatic effect on TS-PDT low-sensitive MKN74 cells. Firstly, in regard of the uptake of TS, there could be expressing several other receptors including albumin receptor ([@b12-ol-0-0-10004]) and heme-carrier protein-1 ([@b13-ol-0-0-10004]) in addition to LDL receptor ([@b6-ol-0-0-10004]). Although LDL receptor could be used for uptake of TS in the gastric cancers, upregulation by simvastatin gave just the partial effect of TS-PDT. Secondly, recent research documented that simvastatin itself has an antitumor effect ([@b14-ol-0-0-10004]), therefore, we did not use higher concentration of simvastatin. In contrast, simvastatin at moderately higher concentrations decreased the viability of MKN74 cells in the TS-PDT *in vitro* model ([Fig. 4D](#f4-ol-0-0-10004){ref-type="fig"}). However, by adding simvastatin to TS-PDT in an *in vitro* system, we could observe that TS-PDT was effective even on resistant cells. The viability (60%) was close to the equivalent with TS-PDT sensitive cell (50%). This datum shows the possibility of combining TS-PDT and simvastatin in clinical practice. Under the criteria of approval by Japanese Universal Health Insurance Coverage System, the efficacy of PDT with Photofrin^®^ for gastric cancer with superficial early gastric cancer was good, with 42 patients (73.7%) out of 57 patients (70 lesions) showed a complete response (Fulfills both 1 and 2). i) No residual tumor at the original lesion examined endoscopically. ii) Biopsy specimen shows no carcinoma cells) ([@b2-ol-0-0-10004]). In the resistant residual or remnant cases despite PDT treatments, simvastatin or similar derivatives might show enhanced/additive effects of PDT, paving the way for novel combination therapy.

On the other hand, remaining cancer stem cells could cause a relapse after anticancer drugs and radiation therapy ([@b15-ol-0-0-10004]). In fact, TS-PDT was rather effective for local failure after CRT or RT alone against superficially localized esophageal cancer ([@b16-ol-0-0-10004]). TS-PDT might be rather effective for aggressive gastric cancer with cancer stem cell appearance, considering the origin of these cell lines; MKN45 cell line was derived from undifferentiated-type gastric cancer, whereas MKN74 cell line was established from differentiated-type gastric cancer. ESD is currently in widespread use for early gastric cancer ([@b17-ol-0-0-10004]). However, when tumors invade the submucosa or have potential risks of metastatic malignancy, additional therapies including surgery would be necessary following ESD ([@b18-ol-0-0-10004]). With a rapidly aging population in Japan, additional surgical intervention is still debatable in particular for elderly patients with high risk comorbidities, suggesting an urgent need for a safer and more efficient therapy in gastric cancer. Therefore, further studies are necessary to evaluate underlying mechanisms of PDT with TS.

In conclusion, LDL receptor expression is involved in the efficacy of TS-PDT. Therefore, simvastatin has the possibility to enhance the effects of TS-PDT as a novel combination therapy.
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![Photodynamic therapy evaluation via proliferation assay. Cell viability was measured at 1 day after LED. \*P\<0.05 vs. each control (n=4). Error bar is expressed as standard error. (A) Treatment time at 4 h with LED power at 2.53 J/cm^2^. (B) Concentration of TS was 10 µM and LED power was 2.53 J/cm^2^. (C) Concentration of TS was 10 µM and irradiation power of LED was 5.06 J/cm^2^. TS, talaporfin sodium.](ol-17-03-3261-g00){#f1-ol-0-0-10004}

![Talaporfin sodium uptake and LDL receptor expression. (A and B) Lysosome was stained green and TS was red (Objective lens, ×10). (C and D) LDL receptor expression by western blotting and reverse transcription-quantitative polymerase chain reaction. \*P\<0.05 vs. MKN-45 (n=3). Error bar is expressed as standard error. LDL, low-density lipoprotein; TS, talaporfin sodium.](ol-17-03-3261-g01){#f2-ol-0-0-10004}

![Determination of GW3965 effect on LDL receptor expression and proliferation. Concentration of GW3965 was 2 µM. Each asterisk was expressed as significant indicator. (A) LDL receptor expression determined by western blotting. (B and C) Cell viability is measured at one day after LED. \*P\<0.05 vs. each control (n=4). Error bar is expressed as standard error. LDL, low-density lipoprotein.](ol-17-03-3261-g02){#f3-ol-0-0-10004}

![Simvastatin effect evaluated by LDL receptor expression and by proliferation assay. Concentration of simvastatin is 20 µM. Each asterisk was expressed as significant indicator. Error bar is expressed as standard error. (A) and (B) LDL receptor expression by western blotting and quantitative PCR. \*P\<0.05 vs. control (n=3). (C) and (D) Cell viability is measured at two days after LED. \*P\<0.05 vs. control (n=4). LDL, low-density lipoprotein.](ol-17-03-3261-g03){#f4-ol-0-0-10004}
